Home > Press > Nanogen Extends IP Portfolio with Nucleic Acid Detection and Genotyping Technology Patents
Nanogen, Inc. (Nasdaq:NGEN), developer of advanced diagnostic products, announced today that it has been granted United States Patent No. 7,252,940, titled "Abasic site endonuclease assay" from the U.S. Patent and Trademark Office. The technology described in the patent extends the underlying proprietary real-time PCR technology used in the Company's MGB Alert® products to a new product offering that has been commercialized as research reagents for use in replication validation following genome wide scanning in pharmaceutical and biotechnology industry labs. This technology is also ideal for genetic analysis in multiplex formats of complex genetic diseases.
Nanogen Extends IP Portfolio with Nucleic Acid Detection and Genotyping Technology Patents
SAN DIEGO, CA | Posted on October 1st, 2007
The unique construct of these assay reagents provides researchers with a method for high throughput validation of SNPs (single nucleotide polymorphisms) discovered during genome wide scanning. The goal of many genome wide scanning projects is to identify SNPs associated with particular diseases, such as diabetes or heart failure, in order to identify therapeutic targets or develop diagnostic assays. In order to establish clear disease association, SNPs are validated across large sample populations, often on the order of tens of thousands. This newly patented technology provides the ability to test large numbers of SNPs in parallel across a large number of samples to complete validation in a relatively rapid manner.
Nanogen has also been awarded U.S. Patent No. 7,205,105, "Real-time linear detection probes: sensitive 5'-minor groove binder-containing probes for PCR analysis," related to the probes employed in its MGB Alert® line of reagents. These probes are an important part of the Company's proprietary product offering designed to assist clinical laboratories in developing molecular diagnostic tests that will detect genetic sequences associated with pathogens including those often tested in immunocompromised patients such as cytomegalovirus, Epstein-Barr virus, and enterovirus.
About Nanogen, Inc.
Nanogen’s advanced technologies provide researchers, clinicians and physicians worldwide with improved methods and tools to predict, diagnose, and ultimately help treat disease. The company's products include real-time PCR reagents, the NanoChip® electronic microarray platform and a line of rapid, point-of-care diagnostic tests. Nanogen’s ten years of pioneering research involving nanotechnology holds the promise of miniaturization and continues to be supported for its potential for diagnostic and biodefense applications.
For more information, please click here
Robert Saltmarsh, Chief Financial Officer, 858-410-4600
Kelly Goodwin, Marketing Communications, 858-410-4688
Copyright © Business Wire 2007
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
UofL scientists uncover how grapefruits provide a secret weapon in medical drug delivery May 22nd, 2013
Single-Cell Transfection Tool Enables Added Control for Biological Studies: McCormick researchers develop method of delivering molecules into targeted cells May 22nd, 2013
How Gold Nanoparticles Can Help Fight Ovarian Cancer May 21st, 2013
MU Researchers Develop Radioactive Nanoparticles that Target Cancer Cells: This is an early step toward developing therapies for metastasized cancers, MU scientist says May 21st, 2013
How do cold ions slide May 24th, 2013
Heinrich Rohrer dies at 79; a father of nanotechnology: With IBM colleague Gerd Binnig, Rohrer invented the scanning tunneling microscope, which can show individual atoms on a surface and move them around May 23rd, 2013
Gold nanocrystal vibration captured on billion-frames-per-second film May 23rd, 2013
Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home: Glowing Plant seeks funds via crowdfunding and raises almost $400,000 May 23rd, 2013
Innovation could bring flexible solar cells, transistors, displays May 22nd, 2013
NanoInk, Inc. Assets To Be Sold May 18th, 2013
HELIOS Program Develops Complete Supply Chain for Integrating Photonics with CMOS Circuit via IC Fabrication Processes May 14th, 2013
Nanotechnology Pioneer Named 'Entrepreneur of the Year': Royal Society of Chemistry honors Chad Mirkin for commercializing innovations May 10th, 2013